Next-generation cancer immunotherapy: the promise of CAR T-Cell therapy.

Chimeric antigen receptor (CAR) T-cell treatment has developed among major substantial improvements for modern cancer treatment, providing sustained responses in patients with otherwise resistant blood cancers. This method comprises of patients reprogramming or donor's T lymphocytes to interpret tumor associated antigens self-sufficiently of major histocompatibility multifaceted presentation, thereby circumventing a key limitation of natural immune surveillance. The approval of CD19- and BCMA-targeted therapies demonstrated remarkable clinical impact and validated the approach. Over successive generations, CAR constructs have been refined with additional costimulatory elements, cytokine support, and multifunctional signaling domains, improving both their persistence and therapeutic activity. Despite such progress, important challenges remain, including risks of relapse, toxicity including neurotoxicity and cytokine release syndrome with limited efficacy in solid tumors. Current research is focused on strategies, such as armored CARs, gene editing, and combination therapies to expand clinical benefit. A comprehensive literature search was conducted using PubMed, Scopus, and Web of Science databases, covering publications from 2000 to 2026 till date. Relevant peer-reviewed articles were selected based on their relevance to CAR T-cell therapy, including preclinical and clinical studies. Detailed search strategy, inclusion criteria, and screening methods are described in the main manuscript. This review explores the evolution, applications, and future outlook of CAR T-cell rehabilitation.